Compare Stocks: AARD, CRMD, CTNM, and RLMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$6.41 -2.4%	$5.59	$3.35 ▼ $17.94	$143.78M	3.81	137,925 shs	130,859 shs
CRMD CorMedix	$8.14 +14.6%	$8.16	$6.13 ▼ $14.96	$557.01M	1.5	925,597 shs	6.07 million shs
CTNM Contineum Therapeutics	$15.30 +2.1%	$14.02	$6.56 ▼ $16.91	$563.57M	0.74	335,807 shs	401,706 shs
RLMD Relmada Therapeutics	$4.75 +0.6%	$5.90	$0.56 ▼ $8.00	$503.48M	0.46	1.65 million shs	1.25 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-2.44%	-12.19%	+2.40%	+40.26%	-42.77%
CRMD CorMedix	+14.65%	+8.39%	-1.57%	+7.81%	-32.62%
CTNM Contineum Therapeutics	+2.14%	-0.33%	+5.01%	+11.52%	+120.14%
RLMD Relmada Therapeutics	+0.64%	-11.55%	-23.51%	-31.16%	+735.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$6.41 -2.4%	$5.59	$3.35 ▼ $17.94	$143.78M	3.81	137,925 shs	130,859 shs
CRMD CorMedix	$8.14 +14.6%	$8.16	$6.13 ▼ $14.96	$557.01M	1.5	925,597 shs	6.07 million shs
CTNM Contineum Therapeutics	$15.30 +2.1%	$14.02	$6.56 ▼ $16.91	$563.57M	0.74	335,807 shs	401,706 shs
RLMD Relmada Therapeutics	$4.75 +0.6%	$5.90	$0.56 ▼ $8.00	$503.48M	0.46	1.65 million shs	1.25 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-2.44%	-12.19%	+2.40%	+40.26%	-42.77%
CRMD CorMedix	+14.65%	+8.39%	-1.57%	+7.81%	-32.62%
CTNM Contineum Therapeutics	+2.14%	-0.33%	+5.01%	+11.52%	+120.14%
RLMD Relmada Therapeutics	+0.64%	-11.55%	-23.51%	-31.16%	+735.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.46	Hold	$16.30	154.29% Upside
CRMD CorMedix	2.75	Moderate Buy	$14.86	82.52% Upside
CTNM Contineum Therapeutics	2.40	Hold	$20.25	32.35% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	152.63% Upside

Current Analyst Ratings Breakdown

Latest AARD, CRMD, CTNM, and RLMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	CRMD CorMedix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/31/2026	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
7/20/2026	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$6.00
7/17/2026	CTNM Contineum Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$14.00 ➝ $13.00
7/2/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/18/2026	RLMD Relmada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/18/2026	RLMD Relmada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/18/2026	RLMD Relmada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/27/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/15/2026	AARD Aardvark Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $7.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$4.90 per share	N/A
CRMD CorMedix	$311.71M	2.05	$2.35 per share	3.47	$5.14 per share	1.58
CTNM Contineum Therapeutics	$50M	11.51	N/A	N/A	$6.37 per share	2.40
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-66.35%	-60.08%	N/A
CRMD CorMedix	$163.05M	$2.13	3.82	814.00	N/A	45.25%	45.57%	24.76%	N/A
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-59.03%	-53.97%	N/A

Latest AARD, CRMD, CTNM, and RLMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRMD CorMedix	$0.2780	$0.29	+$0.0120	$0.29	$96.04 million	$101.93 million
8/11/2026	Q2 2026	AARD Aardvark Therapeutics	-$0.87	-$0.66	+$0.21	-$0.66	N/A	N/A
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A
5/14/2026	Q1 2026	CRMD CorMedix	$0.35	$0.43	+$0.08	$0.43	$104.96 million	$127.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	8.06	8.06
CRMD CorMedix	0.33	2.97	2.74
CTNM Contineum Therapeutics	N/A	37.17	37.17
RLMD Relmada Therapeutics	N/A	18.25	18.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
CRMD CorMedix	34.18%
CTNM Contineum Therapeutics	N/A
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
CRMD CorMedix	3.50%
CTNM Contineum Therapeutics	7.90%
RLMD Relmada Therapeutics	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.88 million	17.99 million	N/A
CRMD CorMedix	30	78.45 million	75.71 million	Optionable
CTNM Contineum Therapeutics	31	37.62 million	34.65 million	N/A
RLMD Relmada Therapeutics	10	106.67 million	91.20 million	Optionable

AARD, CRMD, CTNM, and RLMD Headlines

Recent News About These Companies

HC Wainwright Brokers Increase Earnings Estimates for RLMD

August 13 at 1:43 AM | americanbankingnews.com

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

August 11 at 10:36 AM | zacks.com

Equities Analysts Issue Forecasts for RLMD Q3 Earnings

August 11 at 7:41 AM | marketbeat.com

Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

August 8, 2026 | marketbeat.com

Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 6.8% - Time to Sell?

August 7, 2026 | marketbeat.com

Relmada Therapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | markets.businessinsider.com

Novo Nordisk A/S (NYSE:NVO) and Relmada Therapeutics (NASDAQ:RLMD) Head-To-Head Contrast

August 4, 2026 | americanbankingnews.com

Janus Henderson Group PLC Increases Position in Relmada Therapeutics, Inc. $RLMD

August 2, 2026 | marketbeat.com

597,409 Shares in Relmada Therapeutics, Inc. $RLMD Bought by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Relmada Therapeutics (RLMD) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMD

July 29, 2026 | marketbeat.com

210,525 Shares in Relmada Therapeutics, Inc. $RLMD Bought by Ally Bridge Group NY LLC

July 29, 2026 | marketbeat.com

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

July 28, 2026 | globenewswire.com

Relmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer to Advance NDV-01 and Corporate Growth

July 28, 2026 | quiverquant.comQ

Eversept Partners LP Buys New Shares in Relmada Therapeutics, Inc. $RLMD

July 28, 2026 | marketbeat.com

Relmada Therapeutics, Inc. $RLMD Stock Holdings Increased by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Commodore Capital LP Acquires New Position in Relmada Therapeutics, Inc. $RLMD

July 27, 2026 | marketbeat.com

Spruce Street Capital LP Buys 2,175,933 Shares of Relmada Therapeutics, Inc. $RLMD

July 25, 2026 | marketbeat.com

Knott David M Jr Makes New $3.06 Million Investment in Relmada Therapeutics, Inc. $RLMD

July 24, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, CRMD, CTNM, and RLMD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$6.41 -0.16 (-2.44%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$6.50 +0.09 (+1.48%)

As of 05:38 AM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

CorMedix NASDAQ:CRMD

$8.14 +1.04 (+14.65%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$8.21 +0.07 (+0.91%)

As of 06:16 AM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Contineum Therapeutics NASDAQ:CTNM

$15.30 +0.32 (+2.14%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$15.30 +0.00 (+0.01%)

As of 04:01 AM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Relmada Therapeutics NASDAQ:RLMD

$4.75 +0.03 (+0.64%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$4.62 -0.13 (-2.74%)

As of 04:12 AM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AARD, CRMD, CTNM, and RLMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AARD, CRMD, CTNM, and RLMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AARD, CRMD, CTNM, and RLMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, CRMD, CTNM, and RLMD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

CorMedix NASDAQ:CRMD

Contineum Therapeutics NASDAQ:CTNM

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AARD, CRMD, CTNM, and RLMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AARD, CRMD, CTNM, and RLMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AARD, CRMD, CTNM, and RLMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, CRMD, CTNM, and RLMD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

CorMedix NASDAQ:CRMD

Contineum Therapeutics NASDAQ:CTNM

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools